S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea · Delayed Price · Currency is KRW

19,790

+790 (4.16%)

At close: Aug 20, 2026

-0.65% (1Y)

Market Cap	245.10B +2.8%
Revenue (ttm)	16.48B +5.7%
Net Income	-8.22B
EPS	-683.46
Shares Out	12.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,453
Open	19,890
Previous Close	19,000
Day's Range	19,010 - 20,100
52-Week Range	13,910 - 42,600
Beta	1.45
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2005

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 304360

Full Company Profile

Financial Performance

In 2025, S.Biomedics's revenue was 16.55 billion, an increase of 20.49% compared to the previous year's 13.73 billion. Losses were -8.12 billion, 21.4% more than in 2024.

Financial Statements